Description
Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein (Monomer, MALS verified) | HLE-H82E3-200ug| Gentaur Distribution US, UK & Europe
This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants. The PRAME (SLLQHLIGL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 PRAME (SLLQHLIGL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and PRAME (SLLQHLIGL) peptide.
Source: Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein (HLE-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLQHLIGL peptide (Accession # A0A140T913 (HLA-A*02:01) & P61769 (B2M) & SLLQHLIGL).
Format: Powder.
Tag: C-10×His & C-Avi.
Expression System: HEK293.
Expression Region: Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLQHLIGL peptide.
Conjugate: Biotin-labeled.
Molecular Weight: 36.3 kDa and 11.7 kDa.
Characteristics: Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein is produced by co-expression of HLA and B2M loaded with PRAME peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-45 kDa and 13 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity: 95%.
Buffer: PBS, pH7.4.
Storage Conditions: -20℃.
Shipping Conditions: RT
